Sivifene

Add links
Source: Wikipedia, the free encyclopedia.
Sivifene
Topical
Identifiers
  • 4-[[2-(2,4-Dinitrophenyl)hydrazinyl]-(4-hydroxyphenyl)methylidene]cyclohexa-2,5-dien-1-one
JSmol)
  • C1=CC(=O)C=CC1=C(C2=CC=C(C=C2)O)NNC3=C(C=C(C=C3)[N+](=O)[O-])[N+](=O)[O-]
  • InChI=1S/C19H14N4O6/c24-15-6-1-12(2-7-15)19(13-3-8-16(25)9-4-13)21-20-17-10-5-14(22(26)27)11-18(17)23(28)29/h1-11,20-21,24H
  • Key:JOADKLYQCOMENH-UHFFFAOYSA-N

Sivifene (

invasive carcinomas of the anogenital area such as cervical, vaginal, and anal cancers.[1] The drug reached phase II clinical trials prior to its discontinuation.[1]

Initially, due to its structural similarity to

T-lymphocyte cell surface receptor.[2]

See also

References

  1. ^ a b c "Sivifene - AdisInsight".
  2. ^
    S2CID 10830366
    .
  3. ISBN 978-0-470-69563-0
    .

External links
Retrieved from "https://en.wikipedia.org/w/index.php?title=Sivifene&oldid=1198563038"